Related references
Note: Only part of the references are listed.Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer
Sarah Minner et al.
CLINICAL CANCER RESEARCH (2010)
Pathogenesis of Prostate Cancer
Cheol-Yong Yoon et al.
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION (2010)
Androgen Receptor Expression in Prostate Cancer Cells Is Suppressed by Activation of Epidermal Growth Factor Receptor and ErbB2
Changmeng Cai et al.
CANCER RESEARCH (2009)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis
Rebecca A. Marks et al.
PROSTATE (2008)
Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer
Thorsten Schlomm et al.
CLINICAL CANCER RESEARCH (2007)
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer
Christopher Souder et al.
CANCER (2006)
Regulation of androgen receptor activity by tyrosine phosphorylation
Zhiyong Guo et al.
CANCER CELL (2006)
Post-transcriptional regulation of the androgen receptor by mammalian target of rapamycin
B Cinar et al.
CANCER RESEARCH (2005)
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth
CW Gregory et al.
CLINICAL CANCER RESEARCH (2005)
The androgen axis in recurrent prostate cancer
JL Mohler et al.
CLINICAL CANCER RESEARCH (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy
JS Ross et al.
ONCOLOGIST (2003)
Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function
RM Adam et al.
ENDOCRINOLOGY (2002)
Her-2/neu oncogene amplification in clinically localised prostate cancer
JD Oxley et al.
JOURNAL OF CLINICAL PATHOLOGY (2002)
Her-2-neu expression and progression toward androgen independence in human prostate cancer
S Signoretti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
